Inotrem Receives Milestone Funding From The Crohns & Colitis Foundation Ibd Ventures Program To Advance Its Inflammatory Bowel Disease Pipeline

By Author: Otis
Total Articles: 386
Comment this article

Inotrem is a biotechnology business that is now in an advanced clinical stage and focuses in the research and development of immunotherapies for both acute and chronic inflammatory disorders. The company just recently made the announcement that it has been granted the second round of investment from the IBD Ventures program that is run by the American Crohn's and Colitis Foundation. This funding comes after an earlier round of support that was provided in December 2022 and is predicated on a successful review of Inotrem's interim results, which established the proof of concept for their antibody program, which is referred to as INO-02. INO-02 was developed to target the TREM-1 pathway in order to treat inflammatory bowel disease (IBD), and it also contains a biomarker-based tailored approach in order to identify patients who are most likely to benefit from the treatment. Both of these features were included in order to treat patients in the most effective manner possible.

The Crohn's and Colitis Foundation is a prominent charitable organization that was established with the sole objective of finding a cure for Crohn's ...
... disease and ulcerative colitis. Their choice to continue providing financial support for Inotrem was determined by the fact that the company successfully completed all of the anticipated interim milestones. This research and development effort, which kicked up in January 2023 and is expected to last for more than a year, will be an essential component in Inotrem's preparations for its first clinical study involving humans to test INO-02.

In addition to INO-02, Inotrem also possesses an asset known as nangibotide, which is designed specifically for the treatment of acute inflammatory disorders such as septic shock, COVID-19, and myocardial infarction. The strategy adopted by the company is founded on the cutting-edge, proprietary technology platform it possesses and the strong scientific leadership it possesses in the area of the TREM-1 pathway. Inotrem has developed a broad pharmacological portfolio that targets a number of inflammatory diseases for which there are either no or restricted particular therapy alternatives available at this time.

Read More- https://bit.ly/40qgLrQ